Merck & Co has made another move towards diversifying its pipeline and reducing its reliance on blockbuster cancer drug Keytruda, pledging $525 million to an alliance with Synthekine in
Almirall has licensed an interleukin-2 (IL-2) drug from China's Simcere Pharma, joining the ranks of companies looking at blocking the cytokine as a way to treat autoimmune diseases.
Despite setbacks for projects trying to harness the power of the cytokine interleukin-2 (IL-2) as a cancer therapy, there are still plenty of players on the field – and Roche has just joine
Boehringer Ingelheim must like what it has seen in its two-year-old R&D collaboration with Trutino Biosciences to develop cytokine therapies – it has just taken an option to buy the com
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh